Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Assets (2021 - 2025)

Prime Medicine's Non-Current Assets history spans 5 years, with the latest figure at $161.4 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 88.55% year-over-year to $161.4 million; the TTM value through Dec 2025 reached $637.2 million, up 79.5%, while the annual FY2025 figure was $161.4 million, 88.55% up from the prior year.
  • Non-Current Assets reached $161.4 million in Q4 2025 per PRME's latest filing, up from $153.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $164.4 million in Q1 2025 to a low of $31.3 million in Q4 2021.
  • Average Non-Current Assets over 5 years is $92.3 million, with a median of $85.6 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: skyrocketed 103.65% in 2022, then dropped 20.13% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $31.3 million in 2021, then soared by 103.65% to $63.7 million in 2022, then dropped by 20.13% to $50.9 million in 2023, then soared by 68.3% to $85.6 million in 2024, then surged by 88.55% to $161.4 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Non-Current Assets are $161.4 million (Q4 2025), $153.6 million (Q3 2025), and $157.7 million (Q2 2025).